<code id='C82BCA748E'></code><style id='C82BCA748E'></style>
    • <acronym id='C82BCA748E'></acronym>
      <center id='C82BCA748E'><center id='C82BCA748E'><tfoot id='C82BCA748E'></tfoot></center><abbr id='C82BCA748E'><dir id='C82BCA748E'><tfoot id='C82BCA748E'></tfoot><noframes id='C82BCA748E'>

    • <optgroup id='C82BCA748E'><strike id='C82BCA748E'><sup id='C82BCA748E'></sup></strike><code id='C82BCA748E'></code></optgroup>
        1. <b id='C82BCA748E'><label id='C82BCA748E'><select id='C82BCA748E'><dt id='C82BCA748E'><span id='C82BCA748E'></span></dt></select></label></b><u id='C82BCA748E'></u>
          <i id='C82BCA748E'><strike id='C82BCA748E'><tt id='C82BCA748E'><pre id='C82BCA748E'></pre></tt></strike></i>

          Wikipedia

          Wikipedia

          author:focus    Page View:55
          David L. Ryan/Boston Globe

          A team of high-powered scientists and billionaire investors said Friday that they’re launching a biomedical institute in Cambridge’s Kendall Square with $500 million in private funding with the aim of shortening the path from research breakthroughs to life-saving medicines.

          The institute, called Arena BioWorks, will put drug discovery and company creation under one roof, upending the traditional model where academic research and venture-backed drug development are separate.

          advertisement

          Backed by deep-pocketed investors including Steve Pagliuca, the former co-chair of Bain Capital and Celtics co-owner, and high-tech mogul Michael Dell, Arena has already lured top scientists from academic labs with lucrative compensation packages, but so far has publicly named only a few.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          focus

          Activists slam private health insurers over coverage restrictions
          Activists slam private health insurers over coverage restrictions

          ProtestorsoutsideAmerica'sHealthInsurancePlansheadquarters.CourtesyPeople'sActionWASHINGTON—Hun

          read more
          FDA advisers back CAR
          FDA advisers back CAR

          AdobeApanelofexpertadviserstotheFoodandDrugAdministrationonFridayvotedinfavorofexpandingtheuseofCAR-

          read more
          Dobbs anniversary: the lost opportunity of abortion as health care
          Dobbs anniversary: the lost opportunity of abortion as health care

          NathanHoward/GettyImagesReflectingonthisfirstanniversaryoftheSupremeCourt’sdecisioninDobbstooverturn

          read more

          Amylyx ALS drug fails trial: Relyvrio patients react with fear, worry

          GwenPetersen,38,anALSpatient,believesthattherecentfailureofAmylyx'sdrugRelyvriocouldstillteachresear